Analysis of pretreatment drug resistance and polymorphic sites in CRF08_BC strains among HIV-1 patients
10.3760/cma.j.cn112309-20221212-00403
- VernacularTitle:HIV-1 CRF08_BC亚型感染者治疗前耐药和多态性位点分析
- Author:
Jiaxin ZHANG
1
;
Jing HU
;
Chang SONG
;
Aobo DONG
;
Miaomiao LI
;
Yi FENG
;
Yuhua RUAN
;
Hui XING
;
Lingjie LIAO
Author Information
1. 中国疾病预防控制中心性病艾滋病预防控制中心病毒及免疫研究室，北京 102206
- Keywords:
CRF08_BC;
Pre-antiretroviral treatment;
Drug resistance mutation;
Genetic polymorphism
- From:
Chinese Journal of Microbiology and Immunology
2023;43(1):20-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prevalence of pretreatment drug resistance and the genetic polymorphism of CRF08_BC strains among HIV-1 patients in China.Methods:This cross-sectional survey involved the plasma samples of HIV patients in a national pretreatment HIV drug resistance survey conducted in 2018. RNA was extracted from the samples. The fragments containing protease and partial reverse transcriptase (PR/RT) regions were obtained and sequenced. Drug resistance was analyzed using Stanford HIVdb Program. Differences in polymorphic mutations between drug-resistant and non-drug-resistant HIV-1 strains were analyzed by Chi-square test or Fisher′s exact test. The association between drug-resistant and polymorphic mutations was evaluated using CorMut R package. Molecular transmission networks were constructed using HIV-TRACE software. Results:Totally 465 partial pol sequences were obtained from individuals with CRF08_BC infection in 25 provinces and cities. The total pretreatment drug resistance rate was 17.8% (83/465). The pretreatment drug resistance rates to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) were 16.6% (77/465), 1.1% (5/465) and 0.9% (4/465), respectively. The resistance rate to rilpivirine (RPV) was the highest (15.7%, 73/465). The most common mutation was E138A (11.6%, 54/465). There were six polymorphic mutations (S162C, K102Q, T200A, V179E, I202V, T200M) that co-variated with E138A. The molecular transmission network showed that patients infected with CRF08_BC strains carrying the resistant mutations at position E138 mainly gathered in clusters in Yunnan and Sichuan, and the highest degree of connection was in Lincang, Yunnan. Conclusions:In China, HIV-1 CRF08_BC-infected patients showed a high rate of pretreatment resistance to one of the second-generation NNRTIs, namely RPV. Further researches were warranted to evaluate the impacts of co-mutations of the E138A mutation and polymorphic sites on HIV resistance and replicative capacity.
